P2.04-005 GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC
Year: 2017
Type: article
Study design: Clinical Trial
Source: Journal of Thoracic Oncology
Authors: J. Wolf, J. Han, M. Nishio, P. Souquet, L. Paz-Ares, F. De Marinis, T. Seto, M. De Jonge, T.M. Kim, J. Vansteenkiste, D. Tan, E. Garon, H. Groen, M. Hochmair, E. Felip, N. Reguart, M. Thomas, T. Overbeck, K. Ohashi, M. Giovannini, R. Yura, A. Joshi, M. Akimov, R. Heist
Institutions: University of Cologne, National Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Hôpital Lyon Sud, European Institute of Oncology, National Hospital Organization Kyushu Cancer Center, Erasmus MC Cancer Institute, Seoul National University Hospital, Universitair Ziekenhuis Leuven, National Cancer Centre Singapore, University of California, Los Angeles, University Medical Center Groningen, University of Groningen, Otto Wagner Hospital, Vall d'Hebron Hospital Universitari, Hospital Clínic de Barcelona, Heidelberg University, University Hospital Heidelberg, German Center for Lung Research, University of Göttingen, Okayama University Hospital, Novartis (Switzerland), Novartis (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2952094685